The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006
Open accessAbstract
Purpose: To update the 1999 American Society of Clinical Oncology guideline for antiemetics in oncology. Update Methodology: The Update Committee completed a review and analysis of data published from 1998 thru February 2006. The literature review focused on published randomized controlled trials, and systematic reviews and meta-analyses of published phase II and phase III randomized controlled trials. Recommendations: The three-drug combination of a 5-hydroxytryptamine-3 (5-HT 3) serotonin receptor antagonist, dexamethasone, and aprepitant is recommended before chemotherapy of high emetic risk. For persons receiving chemotherapy of high emetic risk, there is no group of patients for whom agents of lower therapeutic index are appropriate first-choice antiemetics. These agents should be reserved for patients intolerant of or refractory to 5-HT 3 serotonin receptor antagonists, neurokinin-1 receptor antagonists, and dexamethasone. The three-drug combination of a 5-HT 3 receptor serotonin antagonist, dexamethasone, and aprepitant is recommended for patients receiving an anthracycline and cyclophosphamide. For patients receiving other chemotherapy of moderate emetic risk, the Update Committee continues to recommend the two-drug combination of a 5-HT 3 receptor serotonin antagonist and dexamethasone. In all patients receiving cisplatin and all other agents of high emetic risk, the two-drug combination of dexamethasone and aprepitant is recommended for the prevention of delayed emesis. The Update Committee no longer recommends the combination of a 5-HT 3 serotonin receptor antagonist and dexamethasone for the prevention of delayed emesis after chemotherapeutic agents of high emetic risk. Conclusion: The Update Committee recommends that clinicians administer antiemetics while considering patients' emetic risk categories and other characteristics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hesketh, P. J., Grunberg, S. M., Gralla, R. J., Warr, D. G., Roila, F., de Wit, R., Chawla, S. P., Carides, A. D., Ianus, J., Elmer, M. E., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.095 · Cited by 779
Self-citationGralla, R. J., Itri, L. M., Pisko, S. E., Squillante, A. E., Kelsen, D. P., Braun, D. W., Bordin, L. A., Braun, T. J., & Young, C. W. (1981) · New England Journal of Medicine · doi:10.1056/nejm198110153051601 · Cited by 705
Self-citationRecommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines
Gralla, R. J., Osoba, D., Kris, M. G., Kirkbride, P., Hesketh, P. J., Chinnery, L. W., Clark-Snow, R., Gill, D. P., Groshen, S., Grunberg, S., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2971 · Cited by 664
Self-citationProposal for classifying the acute emetogenicity of cancer chemotherapy.
Hesketh, P. J., Kris, M. G., Grunberg, S. M., Beck, T., Hainsworth, J. D., Harker, G., Aapro, M. S., Gandara, D., & Lindley, C. M. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.103 · Cited by 605
Self-citationPoli‐Bigelli, S., Rodrigues‐Pereira, J., Carides, A. D., Julie Ma, G., Eldridge, K., Hipple, A., Evans, J. K., Horgan, K. J., Lawson, F., & On behalf of the Aprepitant Protocol 054 Study Group (2003) · Cancer · doi:10.1002/cncr.11433 · Cited by 564
Gralla, R., Lichinitser, M., Van der Vegt, S., Sleeboom, H., Mezger, J., Peschel, C., Tonini, G., Labianca, R., Macciocchi, A., & Aapro, M. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg417 · Cited by 467
Self-citationWarr, D. G., Hesketh, P. J., Gralla, R. J., Muss, H. B., Herrstedt, J., Eisenberg, P. D., Raftopoulos, H., Grunberg, S. M., Gabriel, M., Rodgers, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.050 · Cited by 463
Self-citationCubeddu, L. X., Hoffmann, I. S., Fuenmayor, N. T., & Finn, A. L. (1990) · New England Journal of Medicine · doi:10.1056/nejm199003223221204 · Cited by 407
Marty, M., Pouillart, P., Scholl, S., Droz, J. P., Azab, M., Brion, N., Pujade-Lauraine, E., Paule, B., Paes, D., & Bons, J. (1990) · New England Journal of Medicine · doi:10.1056/nejm199003223221205 · Cited by 406
Eisenberg, P., Figueroa‐Vadillo, J., Zamora, R., Charu, V., Hajdenberg, J., Cartmell, A., Macciocchi, A., & Grunberg, S. (2003) · Cancer · doi:10.1002/cncr.11817 · Cited by 400
Self-citationReduction of Cisplatin-Induced Emesis by a Selective Neurokinin-1–Receptor Antagonist
Navari, R. M., Reinhardt, R. R., Gralla, R. J., Kris, M. G., Hesketh, P. J., Khojasteh, A., Kindler, H., Grote, T. H., Pendergrass, K., Grunberg, S. M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901213400304 · Cited by 370
Self-citationKris, M. G., Gralla, R. J., Clark, R. A., Tyson, L. B., O'Connell, J. P., Wertheim, M. S., & Kelsen, D. P. (1985) · Journal of Clinical Oncology · doi:10.1200/jco.1985.3.10.1379 · Cited by 336
Self-citation(2006) · Annals of Oncology · doi:10.1093/annonc/mdj078 · Cited by 323
Behavioral Treatment for the Anticipatory Nausea and Vomiting Induced by Cancer Chemotherapy
Morrow, G. R., & Morrell, C. (1982) · New England Journal of Medicine · doi:10.1056/nejm198212093072402 · Cited by 307
Self-citation(1995) · New England Journal of Medicine · doi:10.1056/nejm199501053320101 · Cited by 263
Kris, M. G., Gralla, R. J., Tyson, L. B., Clark, R. A., Cirrincione, C., & Groshen, S. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.1.108 · Cited by 236
Self-citationIoannidis, J. P. A., Hesketh, P. J., & Lau, J. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.19.3409 · Cited by 223
Self-citationChawla, S. P., Grunberg, S. M., Gralla, R. J., Hesketh, P. J., Rittenberg, C., Elmer, M. E., Schmidt, C., Taylor, A., Carides, A. D., Evans, J. K., et al. (2003) · Cancer · doi:10.1002/cncr.11320 · Cited by 217
Self-citationThe Italian Group for Antiemetic Research (2000) · New England Journal of Medicine · doi:10.1056/nejm200005253422102 · Cited by 192
McCrea, J. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00066-3 · Cited by 190
(1998) · Annals of Oncology · doi:10.1023/a:1008471812316 · Cited by 185
Dando, T. M., & Perry, C. M. (2004) · Drugs · doi:10.2165/00003495-200464070-00013 · Cited by 158
Warr, D. G., Grunberg, S. M., Gralla, R. J., Hesketh, P. J., Roila, F., de Wit, R., Carides, A. D., Taylor, A., Evans, J. K., & Horgan, K. J. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.01.024 · Cited by 129
Self-citationHerrstedt, J., Muss, H. B., Warr, D. G., Hesketh, P. J., Eisenberg, P. D., Raftopoulos, H., Grunberg, S. M., Gabriel, M., Rodgers, A., Hustad, C. M., et al. (2005) · Cancer · doi:10.1002/cncr.21343 · Cited by 117
Self-citationKaizer, L., Warr, D. G., Hoskins, P. J., Latreille, J., Lofters, W., Yau, J., Palmer, M. K., Zee, B. C.-Y., Levy, M., & Pater, J. L. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.5.1050 · Cited by 115
Methodology of antiemetic trials: A review
Tonato, M., Roila, F., & Favero, A. D. (1991) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a057871 · Cited by 113
Lofters, W., Pater, J. L., Zee, B. C.-Y., Dempsey, E., Walde, D., Moquin, J.-P., Wilson, K. S., Hoskins, P. J., Guevin, R., Verma, S., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.8.2966 · Cited by 103
Kris, M. G., Hesketh, P. J., Herrstedt, J., Rittenberg, C. N., Einhorn, L. H., Grunberg, S. M., Koeller, J. M., Olver, I., Börjeson, S., & Ballatori, E. (2004) · Supportive Care in Cancer · doi:10.1007/s00520-004-0699-x · Cited by 102
Self-citationGranisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting
del Giglio, A., Soares, H. P., Caparroz, C., & Castro, P. C. (2000) · Cancer · doi:10.1002/1097-0142(20001201)89:11<2301::aid-cncr19>3.0.co;2-6 · Cited by 101
Use of an NK1 Receptor Antagonist to Prevent Delayed Emesis After Cisplatin
Kris, M. G., Pizzo, B. A., Radford, J. E., et al. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.11.817 · Cited by 98
Self-citationLindley, C. M., Bernard, S. A., & Fields, S. M. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.8.1142 · Cited by 96
(1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.9.2937 · Cited by 96
Morrow, G. R. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.10.1170 · Cited by 90
Self-citationBurish, T. G., & Carey, M. P. (1986) · Journal of Consulting and Clinical Psychology · doi:10.1037//0022-006x.54.5.593 · Cited by 87
Andrykowski, M. A., Jacobsen, P. B., Marks, E., Gorfinkle, K., Hakes, T. B., Kaufman, R. J., Currie, V. E., Holland, J. C., & Redd, W. H. (1988) · Cancer · Cited by 83
Danjoux, C. E., Rider, W. D., & Fitzpatrick, P. J. (1979) · Clinical Radiology · doi:10.1016/s0009-9260(79)80203-2 · Cited by 76
Levitt, M., Warr, D. G., Yelle, L., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199304153281503 · Cited by 73
Richter, S. N., Cartei, G., Nadai, M., Trestin, A., Barzon, L., Palumbo, M., & Palù, G. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj944 · Cited by 69
Priestman, T. J., Roberts, J. T., & Upadhyaya, B. K. (1993) · Clinical Oncology · doi:10.1016/s0936-6555(05)80086-x · Cited by 61
Chemotherapy-Related Nausea and Vomiting: Etiology and Management
Morrow, G. R. (1989) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.39.2.89 · Cited by 60
Self-citationRadiotherapy-induced nausea and vomiting (RINV): antiemetic guidelines
Feyer, P. C., Maranzano, E., Molassiotis, A., Clark-Snow, R. A., Roila, F., Warr, D. G., & Olver, I. (2004) · Supportive Care in Cancer · doi:10.1007/s00520-004-0705-3 · Cited by 59
Self-citationModels, Mechanisms and Management of Anticipatory Nausea and Emesis
Morrow, G. R., & Rosenthal, S. N. (2009) · Oncology · doi:10.1159/000227633 · Cited by 48
Self-citationPriestman, S. G., Priestman, T. J., & Canney, P. A. (1987) · Clinical Radiology · doi:10.1016/s0009-9260(87)80151-4 · Cited by 40
Prevention of Cisplatin-Induced Emesis by a Neurokinin-1–Receptor Antagonist
Roila, F., Ballatori, E., & Favero, A. D. (1999) · New England Journal of Medicine · doi:10.1056/nejm199906173402417 · Cited by 38
The delayed-emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo.
Gandara, D. R., Harvey, W. H., Monaghan, G. G., Perez, E. A., Stokes, C., Bryson, J. C., Finn, A. L., & Hesketh, P. J. (1992) · PubMed · Cited by 37
Self-citationJordan, K., Hinke, A., Grothey, A. F., & Schmoll, H. (2004) · Supportive Care in Cancer · doi:10.1007/s00520-004-0672-8 · Cited by 19
Cited by
Cisplatin: The first metal based anticancer drug
Ghosh, S. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.102925 · Cited by 1,751
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
Basch, E., Prestrud, A. A., Hesketh, P. J., Kris, M. G., Feyer, P. C., Somerfield, M. R., Chesney, M., Clark-Snow, R. A., Flaherty, A. M., Freundlich, B., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.4614 · Cited by 1,059
Self-citationAzzoli, C. G., Baker, S., Temin, S., Pao, W., Aliff, T., Brahmer, J., Johnson, D. H., Laskin, J. L., Masters, G., Milton, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.5622 · Cited by 915
Chemotherapy-Induced Nausea and Vomiting
Hesketh, P. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0706547 · Cited by 827
Self-citationPolymorphism of human cytochrome P450 enzymes and its clinical impact
Zhou, S.-F., Liu, J.-P., & Chowbay, B. (2009) · Drug Metabolism Reviews · doi:10.1080/03602530902843483 · Cited by 826
Metadata
- Authors
- Kris, M. G., Hesketh, P. J., Somerfield, M. R., Feyer, P., Clark-Snow, R., Koeller, J. M., Morrow, G. R., Chinnery, L. W., Chesney, M. J., Gralla, R. J., & Grunberg, S. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2006-06-20
- Volume
- 24
- Issue
- 18
- Pages
- 2932-2947
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2158036326
- Cited by
- 740
- References
- 47
- FWCI
- 76.99
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.